Optimisation in the multidisciplinary approach to patients with hepatitis C in the era of direct-acting antivirals
Gastroenterol Hepatol. 2019 Sep:42 Suppl 1:8-13.
doi: 10.1016/S0210-5705(20)30182-5.
Epub 2020 Jun 16.
[Article in
English,
Spanish]
Authors
José Luis Calleja
1
, Ángeles Bermúdez
2
, Ángela Camacho
3
, Francisco Cárdenas
4
, Sergio Fernández
5
, José de Juan
6
, Francisco Jorquera
7
, Manuel Linares
8
, Miguel Ángel Rodríguez
9
, Miriam Romero
10
, Juan Jesús Ruiz
11
, M José Sánchez
12
, Juan de la Vega
13
Affiliations
- 1 Servicio de Gastroenterología, Hospital General Universitario Puerta de Hierro, Madrid, España. Electronic address: joseluis.calleja@uam.es.
- 2 Enfermera de Consulta de Digestivo, Hospital de San Agustín, Avilés, Asturias, España.
- 3 Sección de Enfermedades Infecciosas, Hospital Universitario Reina Sofía, Córdoba, España.
- 4 Servicio de Digestivo, Hospital Comarcal de Antequera, Málaga, España.
- 5 Servicio de Farmacia Hospitalaria, Hospital Comarcal de Antequera, Málaga, España.
- 6 Médico de Atención Primaria, Centro Penitenciario Córdoba, Córdoba, España.
- 7 Servicio de Digestivo, Complejo Asistencial Universitario León, IBIOMED, CIBERehd, España.
- 8 Médico de Atención Primaria, Centro de Salud Buenos Aires, Madrid, España.
- 9 Servicio de Farmacia Hospitalaria, Hospital Universitario Ramón y Cajal, Madrid, España.
- 10 Servicio de Digestivo, Hospital Universitario La Paz, Madrid, España.
- 11 Médico de Atención Primaria Especialista en Adicciones, CTA Málaga, Málaga, España.
- 12 Enfermera de Consulta de Digestivo, Hospital Universitario de Donostia, San Sebastián, España.
- 13 Servicio de Digestivo, Hospital Universitario San Agustín, Avilés, Asturias, España.
Abstract
The advents of current direct-acting antiviral treatments has revolutionised the therapeutic approach to hepatitis C, increasing cure rates to above 90% and substantially simplifying treatment, which translates into benefits for patients, clinicians and the health system. These new drugs allow cure to be achieved, irrespective of the patient's characteristics, with tolerability similar to that of placebo and few drug reactions with concomitant medication. This in turn improves patients' quality of life and wellbeing. Moreover, these drugs allow multidisciplinary optimisation of the approach to patients with hepatitis C, thus reducing both short- and long-term costs. All these factors facilitate treatment universality, with treatments that are less influenced by specific factors and that allow better results to be obtained in a larger number of patients. Elimination of hepatitis C is now a real possibility. Supplement information: This article is part of a supplement entitled "The value of simplicity in hepatitis C treatment", which is sponsored by Gilead. © 2019 Elsevier España, S.L.U. All rights reserved.
Keywords:
Antivirales de acción; Direct-acting antivirals; Hepatitis C; Simplicidad; Simplicity; Tratamiento; Treatment; directa.
Copyright © 2019 Elsevier España, S.L.U. Todos los derechos reservados.
MeSH terms
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use*
-
Cost Savings
-
Drug Interactions
-
Health Facilities
-
Hepatitis C / drug therapy*
-
Hepatitis C / virology
-
Hospitals
-
Humans
-
Primary Health Care
-
Prisons
-
Substance Abuse Treatment Centers
-
Viral Load